DMPK Studies for R&D Efficiency
Pharmaron’s DMPK service helps our partners improve their drug R&D efficiency with our integrated discovery, preclinical and clinical DMPK platforms.
Pharmaron works together with our partners to develop new assays, conduct investigations to support innovative ideas and establish a better model for drug screening and study. In addition, we support IND submission reports, provide clinical research to support phase l and ll clinical trials, as well as offer clinical sample bioanalysis.
AstraZeneca recently published two papers on drug metabolism and disposition focused on prediction of in vivo clearance and plasma concentration for a range of flavin-containing monooxygenase substrates. Pharmaron performed a series of in vitro hepatic stability and protein binding assays, that helped to support this work.
[Drug Metab Dispos, 46 (9) 1259-1267, September 2018]?[Drug Metab Dispos, 45 (10) 1060-1067, October 2017]
Written with permission by AstraZeneca